Sun Pharmaceutical announced the launch of its semaglutide injection under two brand names in India, marking a significant expansion in the company's diabetes and obesity treatment portfolio. The launch includes Noveltreat for weight management and Sematrinity for type 2 diabetes treatment, both priced significantly lower than innovator brands to enhance affordability for Indian patients.

Product Portfolio and Pricing

The company has introduced a comprehensive range of semaglutide injections targeting different therapeutic needs:

Both products are indicated as adjunct therapy to reduced calorie diet and increased physical activity for Noveltreat, and to diet and exercise for Sematrinity.

Product Features and Manufacturing

The semaglutide injections feature advanced delivery systems designed for patient convenience and safety. Noveltreat's prefilled pen incorporates a concealed needle to help ease injection fear and improve both handling safety and dosing accuracy. Sematrinity comes in a multi-dose pen format that offers flexible dosing, equipped with a smooth dialer that enables accurate dose delivery.

The easy-to-use, pre-filled pens are developed by leading global pharmaceutical device suppliers and manufactured in Europe, ensuring high-quality standards and reliability.

Management Commentary and Patient Support

Kirti Ganorkar, Managing Director of Sun Pharmaceutical Industries Ltd, emphasized the company's commitment to accessibility: "With the launch of Noveltreat and Sematrinity, our endeavour is to provide a high-quality, affordable therapy to a wider patient community in India. We are offering a comprehensive range, backed by our decades of expertise in manufacturing complex medicines."

The company is also introducing a holistic patient support program intended to guide patients throughout their treatment journey, providing comprehensive care beyond just medication supply.

Market Context and Healthcare Impact

The launch addresses significant healthcare challenges in India. According to the National Family Health Survey-5 (NFHS-5), almost one in four Indians between the age group 15-49 is now overweight or obese. The ICMR INDIAB 17 study estimated that 101.3 million people had diabetes in India, with about 64% of patients not reaching their HbA1c targets.

GLP-1 agonists, including semaglutide, are considered highly effective treatment options for people with type 2 diabetes mellitus and obesity, while reducing cardiovascular and renal morbidity and mortality. The introduction of affordable alternatives could significantly improve treatment accessibility for Indian patients requiring these advanced therapeutic options.

Sun Pharmaceutical Industries Limited has announced a postal ballot/e-voting process to seek shareholder approval for three important resolutions, as communicated to the stock exchanges on 17 March 2026. The pharmaceutical major is conducting this exercise under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Key Resolutions for Shareholder Approval

The company has proposed three resolutions for shareholder consideration through the postal ballot process:

Cost Auditor Remuneration Details

The first resolution seeks ratification of the remuneration payable to M/s. Narasimha Murthy & Co., Cost Accountants (Firm Registration No. 000042), who have been appointed as Cost Auditors for the financial year 2025-26. The proposed remuneration stands at ₹31,26,000 per annum plus reimbursement of out-of-pocket expenses and applicable taxes. This ratification is required under Section 148(3) of the Companies Act, 2013, read with Companies (Audit and Auditors) Rules, 2014.

Memorandum of Association Amendment for Renewable Energy

The second resolution proposes to amend the company's Memorandum of Association by inserting a new Clause (1B) under Clause III (A) – Main Objects. This amendment will enable the company to undertake power generation activities through various renewable energy sources including hydro, solar, nuclear, and other non-conventional energy sources. The proposed change aligns with the company's sustainability goals and Environmental, Social, and Governance (ESG) principles, allowing it to establish captive power plants and potentially sell surplus power to the grid.

Independent Director Re-appointment

The third resolution concerns the re-appointment of Dr. Pawan Goenka (DIN: 00254502) as an Independent Director for a second term of five years, commencing from 21 May 2026 to 20 May 2031. Dr. Goenka, who currently serves as the Lead Independent Director, will continue to hold office even after attaining the age of 75 years during the proposed term. His extensive experience includes leadership roles at Mahindra & Mahindra Limited and current position as Chairperson of IN-SPACE. Dr. Goenka was honored with the Padma Shri in 2025 for his contributions to the space sector and automotive industry.

E-voting Timeline and Process

The company has established a comprehensive timeline for the postal ballot process:

The company has engaged Central Depository Services (India) Limited (CDSL) as the e-voting service provider. KJB & Co. LLP, Practising Company Secretaries, have been appointed as scrutinizers for the voting process, with Mr. Chintan Goswami as the primary scrutinizer and Mr. Alpesh Panchal as the alternate.

Shareholder Participation Guidelines

Shareholders whose names appear on the Register of Members/List of Beneficial Owners as of the cut-off date of 13 March 2026 will be entitled to participate in the voting process. The voting rights will be proportionate to their shareholding in the paid-up equity share capital of the company. The notice has been sent electronically to shareholders with registered email addresses, and physical copies are not being distributed in accordance with regulatory guidelines.